Literature DB >> 17380368

Patient preferences between surgical and medical treatment in Crohn's disease.

Christopher M Byrne1, Michael J Solomon, Jane M Young, Warwick Selby, James D Harrison.   

Abstract

PURPOSE: Crohn's disease poses difficult choices in which the most appropriate treatment option is not always obvious. When this state of uncertainty exists, patients' preferences should have an increasingly important part of clinical decision making. The purpose of this study was to compare patients' preferences for surgical intervention in Crohn's disease with the preferences of surgeons and gastroenterologists.
METHODS: Outpatients with Crohn's disease were interviewed to quantify their preferences for six scenarios by using the prospective preference measure. An identical questionnaire was mailed to all Australian and New Zealand colorectal surgeons and a random sample of 300 Australian gastroenterologists.
RESULTS: Forty-one of 123 patients with Crohn's disease (33 percent), 92 of 127 colorectal surgeons (72 percent), and 74 of 272 gastroenterologists (27 percent) participated. There were significant differences between patients and gastroenterologists for three of six scenarios and between surgeons and gastroenterologists in four of six scenarios. Seventy-six percent of gastroenterologists were willing to gamble to avoid an ileocolic resection compared with 37 percent of surgeons (chi-squared = 25.44; P < 0.0001) and 39 percent of patients (chi-squared = 15.44; P < 0.001).
CONCLUSIONS: Patients and clinicians were able to trade and gamble life expectancy as a measure of preference for varying hypothetical surgical treatments, even though these treatment options impacted on quality of life rather than survival. Patients' preferences did not align with clinicians. For most scenarios, colorectal surgeons' preferences were significantly different to those of gastroenterologists.

Entities:  

Mesh:

Year:  2007        PMID: 17380368     DOI: 10.1007/s10350-006-0847-0

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

Review 1.  Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data.

Authors:  Meenakshi Bewtra; F Reed Johnson
Journal:  Patient       Date:  2013       Impact factor: 3.883

2.  Short-term outcomes of laparoscopic surgery for Crohn's disease patients treated with anti-tumor necrosis factor alpha agents.

Authors:  Tsuyoshi Hata; Tsunekazu Mizushima; Hideki Osawa; Hidekazu Takahashi; Naotsugu Haraguchi; Junichi Nishimura; Taishi Hata; Ichiro Takemasa; Masakazu Ikenaga; Kiyokazu Nakajima; Hirofumi Yamamoto; Kohei Murata; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2016-07-02       Impact factor: 2.549

3.  Patients' perspective on bowel resection for inflammatory bowel disease.

Authors:  Milton Mui; Vinna An; Jane Lovell; Basil D'Souza; Rodney Woods
Journal:  Int J Colorectal Dis       Date:  2017-12-04       Impact factor: 2.571

4.  Defining the optimal design of the inflammatory bowel disease multidisciplinary team: results from a multicentre qualitative expert-based study.

Authors:  Pritesh Morar; Jamie Read; Sonal Arora; Ailsa Hart; Janindra Warusavitarne; James Green; Nick Sevdalis; Cathryn Edwards; Omar Faiz
Journal:  Frontline Gastroenterol       Date:  2015-03-26

5.  Preferences related to attention-deficit/hyperactivity disorder and its treatment.

Authors:  Kate Van Brunt; Louis S Matza; Peter M Classi; Joseph A Johnston
Journal:  Patient Prefer Adherence       Date:  2011-01-17       Impact factor: 2.711

6.  Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients.

Authors:  Kweku A Appau; Victor W Fazio; Bo Shen; James M Church; Bret Lashner; Feza Remzi; Aaron Brzezinski; Scott A Strong; Jeffrey Hammel; Ravi P Kiran
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

Review 7.  Assessing internet-based information used to aid patient decision-making about surgery for perianal Crohn's fistula.

Authors:  J H Marshall; D M Baker; M J Lee; G L Jones; A J Lobo; S R Brown
Journal:  Tech Coloproctol       Date:  2017-06-22       Impact factor: 3.781

Review 8.  Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors.

Authors:  Susan Hua
Journal:  Front Pharmacol       Date:  2020-04-28       Impact factor: 5.810

Review 9.  Shared decision-making in the management of patients with inflammatory bowel disease.

Authors:  Kai Song; Dong Wu
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

10.  Oral Delivery of Nanoparticles Loaded With Ginger Active Compound, 6-Shogaol, Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis.

Authors:  Mingzhen Zhang; Changlong Xu; Dandan Liu; Moon Kwon Han; Lixin Wang; Didier Merlin
Journal:  J Crohns Colitis       Date:  2018-01-24       Impact factor: 9.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.